Drug Approval | October 26, 2021
Glenmark launches novel fixed-dose combination for diabetes
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
Collaboration designed to bring reproductive health screening capabilities to hospitals and clinics across the country
This unique record was made possible by collating hard copies of the books in a structured manner
India reports 18 lakh stroke cases a year with 25 per cent patients below the age of 50
Invisible Nation is a worldwide network of patient organizations committed to driving a decline in cardiovascular (CV) death by effecting systemic change in atherosclerotic cardiovascular disease (ASCVD) care
By combining Innovaccer's Data Activation Platform with HCL's robust healthcare data accelerator (hDATA) suite, organizations can enable patient-centricity, cost-optimization and compliance
The company proposes to invest up to US $ 50 million, over a period of five years, starting from FY22, to support capability development of talent and technology
The division is expected to grow to over a 100-member strong team by 2022
The first patient dosed with VX-880 demonstrated restoration of insulin production and achieved C-peptide of 560 pmol/L in response to Mixed Meal Tolerance Test (MMTT) at Day 90 visit
The trial met the primary endpoint of overall survival with a single priming dose of tremelimumab plus Imfinzi every four weeks vs. sorafenib
Subscribe To Our Newsletter & Stay Updated
